Literature DB >> 31857977

Head and Neck Tumors: Management of Primary Undifferentiated Pleomorphic Sarcoma.

Luis-Alejandro Boccalatte1, Natalia-Lucía Gómez1, Alejandro Yanzon1, Eduardo-Luis Mazzaro1, Federico Cayol2, Marcelo-Fernando Figari1.   

Abstract

INTRODUCTION: Sarcomas account for 1% of all tumors originated in the head and neck regions in adults. They constitute a heterogeneous group of tumors of mesenchymal origin with multiple histological variants. The undifferentiated pleomorphic sarcoma (UPS) subtype is the most frequent variant with an incidence range of 2.7-38%.
MATERIALS AND METHODS: This retrospective case series was conducted on 11 patients who were diagnosed with UPS and treated in our institution in the last 11 years.
RESULTS: According to the results, 26.8% of the sarcomas corresponded to UPS variant. Out of 11 patients, 5 cases were female. The median age of the participants was 58 years (range: 18-74 years). Seven and four patients were T1b and T2b, respectively. Ten patients had no metastasis at the moment of diagnosis. Six patients were categorized as intermediate-grade, and the remaining (n=5) were classified as high-grade. The most frequent location was the scalp (n=3). In the patients undergoing surgery, the mean follow-up duration was 52 months. Disease-free survival (DFS) rates were obtained at 70%, 50%, and 50% in the 1st, 3rd, and 5th years, respectively, with the mean DFS of 36 months. In addition, the overall survival rates in the 1st, 3rd, and 5th years were 100%, 100%, and 83%, respectively.
CONCLUSION: The UPS represented the most common histological subtype in our series. They tend to be intermediate or high-grade tumors. An acceptable global survival rate justifies surgical treatment as the main therapeutic tool.

Entities:  

Keywords:  Head; Neck; Neoplasms; Sarcomas; Undifferentiated pleomorphic sarcomas

Year:  2019        PMID: 31857977      PMCID: PMC6914320          DOI: 10.22038/ijorl.2019.30195.1990

Source DB:  PubMed          Journal:  Iran J Otorhinolaryngol        ISSN: 2251-7251


  40 in total

1.  Sarcoma arising in irradiated bone; report of 11 cases.

Authors:  W G CAHAN; H Q WOODARD
Journal:  Cancer       Date:  1948-05       Impact factor: 6.860

2.  Long-term salvageability for patients with locally recurrent soft-tissue sarcomas.

Authors:  S Singer; K Antman; J M Corson; T J Eberlein
Journal:  Arch Surg       Date:  1992-05

3.  Treatment of soft tissue sarcomas by preoperative irradiation and conservative surgical resection.

Authors:  H T Barkley; R G Martin; M M Romsdahl; R Lindberg; G K Zagars
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-04       Impact factor: 7.038

4.  Prognostic factors for recurrence and survival in head and neck soft tissue sarcomas.

Authors:  D H Kraus; S Dubner; L B Harrison; E W Strong; S I Hajdu; U Kher; C Begg; M F Brennan
Journal:  Cancer       Date:  1994-07-15       Impact factor: 6.860

5.  Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas.

Authors:  S R Patel; S Vadhan-Raj; M A Burgess; C Plager; N Papadopolous; J Jenkins; R S Benjamin
Journal:  Am J Clin Oncol       Date:  1998-06       Impact factor: 2.339

Review 6.  Sarcomas of the head and neck region.

Authors:  Thomas D Shellenberger; Erich M Sturgis
Journal:  Curr Oncol Rep       Date:  2009-03       Impact factor: 5.075

Review 7.  Postirradiation sarcomas. A single-institution study and review of the literature.

Authors:  R J Mark; J Poen; L M Tran; Y S Fu; M T Selch; R G Parker
Journal:  Cancer       Date:  1994-05-15       Impact factor: 6.860

8.  Head and neck soft tissue sarcoma.

Authors:  A S Aljabab; R W Nason; R Kazi; K A Pathak
Journal:  Indian J Surg Oncol       Date:  2012-03-06

Review 9.  The evolving classification of soft tissue tumours - an update based on the new 2013 WHO classification.

Authors:  Christopher D M Fletcher
Journal:  Histopathology       Date:  2013-10-25       Impact factor: 5.087

Review 10.  Head and neck sarcomas: epidemiology, pathology, and management.

Authors:  James Paul O'Neill; Mark H Bilsky; Dennis Kraus
Journal:  Neurosurg Clin N Am       Date:  2013-01       Impact factor: 2.509

View more
  3 in total

1.  Nomogram for predicting cancer-specific survival in undifferentiated pleomorphic sarcoma: A Surveillance, Epidemiology, and End Results -based study.

Authors:  Fengshuo Xu; Fanfan Zhao; Xiaojie Feng; Chengzhuo Li; Didi Han; Shuai Zheng; Yue Liu; Jun Lyu
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

2.  Undifferentiated pleomorphic sarcoma of the extremity and trunk: a retrospective cohort study of 166 cases in a large institution.

Authors:  Shuguang Zhang; Xinxin Zhang; Zhenguo Zhao; Libin Xu; Songfeng Xu; Ting Liu; Shengji Yu
Journal:  Transl Cancer Res       Date:  2022-04       Impact factor: 0.496

3.  Head and Neck Sarcomas-clinicopathological Findings, Treatment Modalities and Its Outcome - A Retrospective Study.

Authors:  Hari Ram; Satish Kumar; S N Singh; Pramod Kumar; Geeta Singh; Roop Ganguly; Mala Sagar; Debraj Howlader
Journal:  Ann Maxillofac Surg       Date:  2022-02-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.